NCT02896192View on ClinicalTrials.gov

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions
Pro-opiomelanocortin (POMC) Deficiency Obesity
Interventions
DRUG

Setmelanotide

Once daily SC injection

DRUG

Placebo

Once daily SC injection

Trial Locations (7)

9000

UZ Gent, Ghent

13353

Charité Campus Virchow-Klinikum / Institute for Experimental Pediatric Endocrinology, Berlin

28009

Hospital Universitario Niño Jesús, Madrid

75013

Institute of Cardiometabolism and Nutrition / Hopital de la Pitié-Salpêtrière, Paris

85258

Honor Health Research Institute, Scottsdale

L6W 2Z8

Peel Memorial Hospital, Brampton

CB2 0QQ

University of Cambridge Metabolic Research Laboratories, Cambridge

All Listed Sponsors
lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY

NCT02896192 - Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | Biotech Hunter | Biotech Hunter